Four findings that reframed the brand's win-back strategy
A digitally native serum brand losing users it should have kept
Lumact is a digitally native skincare brand in India's active-ingredient serum category, built on ingredient transparency and formulation credibility. Despite genuine product differentiation, internal data pointed to meaningful user churn the brand lacked consumer intelligence to explain or address.
Lumact needed to decide whether to reposition, reformulate, or both. Existing assumptions about why users lapsed were internal and unvalidated, and leadership suspected the brand was not owning proof-based territory it had legitimately earned.
Four questions that defined the research
A structured Gainer-Lapser study built to isolate switching triggers in both directions
Rather than surveying a general category audience, Flickly recruited two discrete cohorts, current users who had recently switched to the brand, and former users who had recently left, enabling a direct comparison of acquisition and attrition drivers.
Survey architecture
A routed questionnaire covering skin profile, brand journey, product experience, pricing expectations, ingredient awareness, switching triggers, and concept testing across three candidate positioning territories.
Gainer-Lapser cohort design
Two discrete cohorts were recruited, current users who had recently switched to the brand, and former users who had recently left, enabling a direct comparison of acquisition and attrition drivers.
Audience and bias control
100 confirmed Niacinamide serum users across Indian metros, evenly split between Gainers and Lapsers. Cohort qualification was rigorously screened for recency of usage and discontinuation to reduce recall distortion.
Forced-choice concept testing
Three positioning concepts were tested in randomised order with forced-choice purchase preference and trust measures to reveal decision-stage behaviour beyond stated appeal.
Slow visible results, not price or side effects, is the core lapse trigger
- 36% cited slow results and 46% saw no change after four weeks, making a credible four-week proof claim the strongest recovery lever.
- Lapsers are switching to perceived credibility, not necessarily better products: 30% chose replacements for clinical proof and 30% for dermatologist recommendation.
- Clinical proof is the category's highest-authority claim, rated important by 92% of respondents, outperforming ingredient concentration and delivery technology.
- 86% of Lapsers would try an upgraded version, but only if the improvement story is specific and credible.
